Skip to main content

Table 3 Per-cancer Therapy Efficacy model performance assessed using overall survival

From: The impact of pharmacokinetic gene profiles across human cancers

 

Univariateb

Multivariatec

 

HR [95% CI]a

p-value

HR [95% CI]

p-value

GBM

0.87 [0.38, 2.01]

7.5 × 10− 1

1.84 [1.17, 2.89]

7.9 × 10− 3

BRCA

1.96 [0.75, 5.12]

1.7 × 10−1

1.80 [1.40, 2.30]

3.0 × 10−6

OV

1.56 [0.94, 2.57]

8.4 × 10−2

1.46 [0.88, 2.42]

1.4 × 10− 1

KIRC

7.75 [3.25, 18.50]

3.9 × 10− 6

3.07 [2.18, 4.33]

1.7 × 10− 10

LUAD

1.53 [0.47, 4.94]

4.8 × 10−1

1.65 [0.94, 2.91]

8.0 × 10− 2

UCEC

1.60 [0.48, 5.32]

4.4 × 10−1

0.94 [0.58, 1.54]

8.1 × 10− 1

HNSC

1.39 [0.63, 3.08]

4.2 × 10−1

1.59 [1.05, 2.42]

2.9 × 10−2

LUSC

0.67 [0.21, 2.14]

4.9 × 10−1

0.63 [0.35, 1.12]

1.2 × 10−1

  1. aThe hazard ratio (HR) and the bounds of its 95% confidence interval (CI)
  2. bThe HR associated with being in the high-risk cohort
  3. cThe HR associated with being in the high-risk cohort, after accounting for clinical covariates as itemized in Table 1
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us